Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)

27. oktober 2026 oppdatert av: Astellas Pharma Global Development, Inc.

A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE ENFORTUMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PARTICIPANTS WITH MUSCLE-INVASIVE BLADDER CANCER WHO ARE INELIGIBLE FOR OR HAVE ELECTED NOT TO UNDERGO CYSTECTOMY

This study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab) work together as a bladder preservation approach to treat patients with muscle invasive bladder cancer. The study will compare these drugs to concurrent chemoradiotherapy that is usually used to treat this cancer (standard of care). The study will enroll patients with muscle-invasive bladder cancer (MIBC) who have cancer that has not spread outside the bladder.

Studieoversikt

Detaljert beskrivelse

This study is being conducted to evaluate the combination of enfortumab vedotin + pembrolizumab versus standard of care concurrent chemoradiotherapy, in subjects with previously untreated muscle invasive bladder cancer.

Enfortumab vedotin may be administered for up to 9 cycles or a protocol defined reason for study discontinuation occurs, whichever is first. Pembrolizumab may be administered for a maximum of 17 cycles (3-week cycles) or a protocol-defined reason for study discontinuation occurs, whichever is first. Concurrent chemoradiotherapy may be administered for a maximum of 6.5 weeks.

Studietype

Intervensjonell

Registrering (Antatt)

390

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Quebec
      • Chicoutimi, Quebec, Canada
        • Rekruttering
        • Site CA01194
      • Montreal, Quebec, Canada
        • Rekruttering
        • Site CA01071
      • Montreal, Quebec, Canada
        • Rekruttering
        • Site CA01052
    • Arkansas
      • Little Rock, Arkansas, Forente stater, 72211
        • Rekruttering
        • Arkansas Urology
    • California
      • Santa Barbara, California, Forente stater, 93105
        • Rekruttering
        • Samsun Clinic - Ridley-Tree Cancer Center
    • Colorado
      • Aurora, Colorado, Forente stater, 80012
        • Rekruttering
        • Rocky Mountain Cancer Center
    • Delaware
      • Newark, Delaware, Forente stater, 19713
        • Rekruttering
        • Medical Oncology Hematology Consultants
    • Illinois
      • Hinsdale, Illinois, Forente stater, 60521
        • Rekruttering
        • Hope and Healing Clinical Research LLC
      • New Lenox, Illinois, Forente stater, 60451
        • Rekruttering
        • Hope and Healing Clinical Research LLC
      • Niles, Illinois, Forente stater, 60714
        • Rekruttering
        • Illinois Cancer Specialists
    • Indiana
      • Fort Wayne, Indiana, Forente stater, 46825
        • Rekruttering
        • Fort Wayne Medical Oncology and Hematology
    • Michigan
      • Royal Oak, Michigan, Forente stater, 48073
        • Rekruttering
        • Comprehensive Urology
    • Missouri
      • Columbia, Missouri, Forente stater, 65201
        • Rekruttering
        • Missouri Cancer Associates
      • St Louis, Missouri, Forente stater, 63110
        • Rekruttering
        • Siteman Cancer Center
    • Nevada
      • Las Vegas, Nevada, Forente stater, 89106
        • Rekruttering
        • Comprehensive Cancer Centers of Nevada - Southwest
    • New York
      • New York, New York, Forente stater, 10029
        • Rekruttering
        • Icahn School of Medicine at Mount Sinai
    • Ohio
      • Fairfield, Ohio, Forente stater, 45014
        • Rekruttering
        • Oncology Hematology Care Clinical Trials, LLC
    • Oregon
      • Eugene, Oregon, Forente stater, 97401
        • Rekruttering
        • Williamette Valley Cancer Institute and Research Center
      • Tigard, Oregon, Forente stater, 97223
        • Rekruttering
        • Compass Oncology - West
    • Tennessee
      • Nashville, Tennessee, Forente stater, 37203
        • Rekruttering
        • SCRI Oncology Partners
    • Texas
      • Austin, Texas, Forente stater, 78705
        • Rekruttering
        • Texas Oncology
      • Tyler, Texas, Forente stater, 75702
        • Rekruttering
        • Texas Oncology - Northeast Texas
    • Virginia
      • Charlottesville, Virginia, Forente stater, 22903
        • Rekruttering
        • University of Virginia Comprehensive Cancer Center
      • Norfolk, Virginia, Forente stater, 23502
        • Rekruttering
        • Virginia Oncology Associates
      • Daegu, Sør -Korea
        • Rekruttering
        • Site KR01113
      • Seongnam-si, Sør -Korea
        • Rekruttering
        • Site KR01063
      • Seoul, Sør -Korea
        • Rekruttering
        • Site KR01065
      • Seoul, Sør -Korea
        • Rekruttering
        • Site KR01084
      • Kaohsiung City, Taiwan
        • Rekruttering
        • Site TW01117

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Has histologically confirmed initial diagnosis of muscle-invasive bladder cancer (MIBC) with predominant urothelial histology staged cT2-T4aN0M0
  • Tissue comprising muscle-invasive urothelial cancer must be submitted for clinical staging at baseline
  • Eligible for and agree to receive chemoradiotherapy and one of the protocol-specified radiosensitizing chemotherapy regimens
  • Fit for systemic therapy and elect bladder preservation, including participants who are ineligible for or have elected not to undergo cystectomy
  • Has Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

Exclusion Criteria:

  • Advanced or metastatic disease (N+, M1), non-urothelial carcinoma, diffuse or multifocal CIS, urothelial carcinoma or histological variant at any site outside the urinary bladder within previous 24 months prior to randomization except Ta/T1/CIS of the upper urinary tract including renal pelvis and ureter if the participant had undergone complete nephrectomy
  • Has received any prior systemic treatment, chemoradiation, and/or radiation for MIBC or NMIBC
  • Prior pelvic radiation for any reason
  • Inadequate bladder function
  • Other active malignancies within 3 years prior to randomization
  • Previously treated with enfortumab vedotin or other MMAE-based antibody-drug conjugates (ADCs)
  • Previously treated with a PD(L)-1 inhibitor, defined as a PD-1 inhibitor or PD-L1 inhibitor
  • Uncontrolled diabetes
  • Currently receiving systemic antimicrobial treatment for active infection (viral, bacterial, or fungal) at the time of randomization. Routine antimicrobial prophylaxis is permitted
  • Known active hepatitis B, active hepatitis C, or human immunodeficiency virus (HIV) infection
  • Received major surgery (defined as requiring general anesthesia and >24 hour inpatient hospitalization) within 4 weeks prior to randomization
  • Known severe (≥ Grade 3) hypersensitivity to any enfortumab vedotin excipient contained in the drug formulation of enfortumab vedotin
  • Known genetic disorders associated with radiosensitivity (eg, ataxia telangiectasia, Nijmegen breakage syndrome, Fanconi syndrome)
  • Active keratitis or corneal ulcerations
  • History of autoimmune disease that has required systemic treatment in the past 2 years
  • History of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
  • Prior allogeneic stem cell or solid organ transplant
  • Received a live attenuated vaccine within 30 days prior to randomization

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Arm A

Enfortumab vedotin + pembrolizumab (EV + P)

Enfortumab vedotin administered as an IV infusion on Days 1 and 8 of every 3-week cycle up to cycle 9.

Andre navn:
  • • Padcev
  • • ASG-22CE
  • • ASG-22Me

IV infusion on Day 1 of every 3-week cycle up to cycle 17.

Andre navn:
  • Keytruda
Aktiv komparator: Arm B

Concurrent Chemoradiotherapy (cCRT)

64 Gy in 32 fractions over 6.5 weeks administered to the participant's bladder only or the bladder and prophylactically to pelvic nodes.

55 Gy in 20 fractions over 4 weeks administered to the participant's bladder only.

40 mg of cisplatin per meter squared of body surface area, administered once weekly via IV infusion during radiation OR 20 mg of cisplatin per meter squared of body surface area per day on Days 1 and 2 weekly via IV infusion during radiation.

500 mg per meter squared of body surface area per day on Days 1-5 (week 1) and Days 22 26 (week 3) administered as continuous IV infusion during radiation in combination with mitomycin C.

Andre navn:
  • • 5-Fluorouracil
  • • 5-FU

12 mg per meter squared of body surface area administered as an IV bolus on Day 1 during radiation in combination with fluorouracil.

Andre navn:
  • • MMC

100 mg per meter squared of body surface area administered once weekly via IV infusion during radiation OR 27 mg per meter squared of body surface area administered twice weekly via IV infusion during radiation

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Bladder-intact Event Free Survival (BI-EFS) by Blinded Independent Central Review (BICR)
Tidsramme: Up to approximately 45.5 months

BI-EFS is defined as the time from randomization to any of the following events: histologically confirmed persistent or residual MIBC post-treatment confirmed by BICR, histologically confirmed recurrent MIBC by BICR, disease progression by BICR, cystectomy, or death from any cause.

Up to approximately 45.5 months
Overall Survival (OS)
Tidsramme: Up to approximately 60 months

Time from randomization to death due to any cause.

Up to approximately 60 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Bladder-intact Event Free Survival (BI-EFS) by Investigator
Tidsramme: Up to approximately 45.5 months

BI-EFS is defined as the time from randomization to any of the following events: histologically confirmed persistent or residual MIBC post-treatment, histologically confirmed recurrent MIBC, disease progression, cystectomy, or death from any cause.

Up to approximately 45.5 months
Complete clinical response (cCR) rate by Blinded Independent Central Review (BICR) and Investigator
Tidsramme: Up to approximately 60 months

cCR is defined as no radiographic evidence of residual or metastatic disease on imaging, negative cystoscopy, negative pathology except for low-grade Ta, and negative urine cytology.

Up to approximately 60 months
Metastasis-Free Survival (MFS) by Blinded Independent Central Review (BICR) and Investigator
Tidsramme: Up to approximately 60 months]

Time from randomization to radiologically or pathologically confirmed distant metastasis, or death due to any cause, whichever occurs first.

Up to approximately 60 months]
Time to Cystectomy
Tidsramme: Up to approximately 60 months

The time from randomization to cystectomy.

Up to approximately 60 months
Disease Free Survival (DFS) by Blinded Independent Central Review (BICR) and Investigator
Tidsramme: Up to approximately 60 months

The time from cCR to local recurrence or distant metastases, a second primary bladder cancer, or death due to any cause, whichever occurs first.

Up to approximately 60 months
Cystectomy Free Survival (CFS)
Tidsramme: Up to approximately 60 months

The time from randomization to cystectomy or death due to any cause, whichever occurs first.

Up to approximately 60 months
Number of Participants with Treatment Emergent Adverse Event (TEAE)
Tidsramme: From start of study treatment up to 30 days after last dose of study drug (approximately up to 1.1 years)

An AE is any untoward medical occurrence in a participant who receives a study treatment without regard to possibility of causal relationship. Treatment-emergent are events between the first dose of study treatment and up to 30 days after the last dose that were absent before treatment or that worsened relative to pretreatment state.

From start of study treatment up to 30 days after last dose of study drug (approximately up to 1.1 years)
Number of Participants with Serious TEAEs
Tidsramme: From start of treatment up to 90 days after the last dose of study treatment (approximately up to 1.3 years)

An SAE is any AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/ incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 90 days after last dose that were absent before treatment or that worsened relative to pretreatment state.

From start of treatment up to 90 days after the last dose of study treatment (approximately up to 1.3 years)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Samarbeidspartnere

Etterforskere

  • Studieleder: Zejing Wang, MD/PhD, Pfizer

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

11. mai 2026

Primær fullføring (Antatt)

31. mars 2030

Studiet fullført (Antatt)

29. februar 2032

Datoer for studieregistrering

Først innsendt

29. april 2026

Først innsendt som oppfylte QC-kriteriene

29. april 2026

Først lagt ut (Faktiske)

4. mai 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

28. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

27. oktober 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • C5701009
  • EV-309 (Annen identifikator: Alias Study Number)
  • 2026-525612-34-00 (Ctis)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

UBESLUTTE

IPD-planbeskrivelse

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere